https://www.washingtonpost.com/news/to-your-health/wp/2016/08/03/nih-to-begin-testing-zika-vaccine-in-humans/?tid=hybrid_collaborative_3_na

As the Zika virus continues its spread, infecting people in more than 50 countries and threatening fetal development in pregnant women, scientists have been racing to develop an effective vaccine for the disease.

Federal researchers on Wednesday announced a milestone in that effort: their first clinical trial in humans.

The trial will involve at least 80 healthy volunteers between ages 18 and 35 at three locations around the United States, including at the National Institutes of Health Clinical Center in Bethesda. The main goal of the study will be to evaluate the vaccine’s safety and to see whether it generates an immune-system response in patients. If those early results are positive, researchers hope to began a larger-scale trial in Zika-affected countries in early 2017.

“A safe and effective vaccine to prevent Zika virus infection and the devastating birth defects it causes is a public health imperative,” Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a statement. “NIAID worked expeditiously to ready a vaccine candidate, and results in animal testing have been very encouraging. We are pleased that we are now able to proceed with this initial study in people. Although it will take some time before a vaccine against Zika is commercially available, the launch of this study is an important step forward.”